Department of Dental Clinical Specialties, Faculty of Dentistry, Universidad Complutense de Madrid, Pza Ramón y Cajal s/n, 28048, Madrid, Spain.
ETEP (Etiology and Therapy of Periodontal Diseases) Research Group. Faculty of Dentistry, Universidad Complutense de Madrid, Madrid, Spain.
Support Care Cancer. 2019 Sep;27(9):3479-3490. doi: 10.1007/s00520-019-4650-6. Epub 2019 Jan 24.
To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients.
A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient's oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient's periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups.
Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001).
The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.
确定化疗引起的口腔不良反应的报告发生率和患者自我报告的口腔不良反应发生率，并探讨这两种发生率是否与患者的牙周病患病风险相关。
进行了一项横断面研究，纳入正在接受化疗治疗的患者。在接受化疗输液期间，收集患者的人口统计学、口腔卫生习惯和癌症相关数据。采用医院环境下患者口腔评估指南来评估患者的口腔状况，使用视觉模拟量表来评估患者相关结局（PROMs），同时采用经过验证的问卷来评估患者的牙周病患病风险。采用均数和标准差（SD）表示定量变量的数据，采用计数、发生率和 95%置信区间（CI）表示定性变量的数据。采用方差分析和卡方检验比较不同牙周病患病风险组之间的口腔不良反应发生率。
本研究共纳入 369 名患者。专业报告的口腔不良反应发生率为 86.99%（95%CI 83.54%；90.44%）。自我报告的口腔不良反应发生率为 89.70%（95%CI 86.59%；92.82%）。最常见的口腔不良反应为口干（73.4%）、味觉障碍（61.8%）和唇干（54.2%）。牙周病患病风险较高的患者出现更多的口腔改变（p<0.001）。
正在接受化疗的患者中，口腔不良反应（专业或自我报告）的发生率高于 85%。随着牙周病患病风险的增加，这种发生率也会增加。
